Evaluating FAP as a biomarker for fibrotic lung diseases
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
This study is testing if a protein called FAP can help doctors understand and track fibrotic lung diseases like idiopathic pulmonary fibrosis by looking at its levels in different samples and using special scans before and after treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasme University Hospital Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT06189820 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the fibroblast activation protein (FAP) as a biomarker for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF) and other non-IPF interstitial lung diseases (ILDs). It will involve analyzing FAP expression in various biological samples and using FAPI PET/CT scans to evaluate fibrotic activity before and after initiating different treatments, such as antifibrotic therapy, corticosteroids, and immunosuppressive drugs. The study will also correlate FAP expression with findings from lung biopsies or surgeries.
Who should consider this trial
Good fit: Ideal candidates include adult patients diagnosed with fibrotic lung diseases, specifically idiopathic pulmonary fibrosis or non-IPF ILDs.
Not a fit: Patients who are pregnant, nursing, or have significant comorbidities that may interfere with the study will not benefit from participation.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients with fibrotic lung diseases.
How similar studies have performed: While the use of FAP as a biomarker is a relatively novel approach, similar studies have shown promise in evaluating biomarkers for fibrotic diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines Exclusion Criteria: * Pregnant or nursing patients * Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. * Patients with an active lung neoplasm or any active neoplasm for blood samples
Where this trial is running
Brussels
- Medecine — Brussels, Belgium (Recruiting)
Study contacts
- Study coordinator: Benjamin Bondue
- Email: benjamin.bondue@hubruxelles.be
- Phone: + 32 (2) 555 5758
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.